期刊文献+

男性肥胖隐性高血压患者血清同型半胱氨酸及高敏C反应蛋白水平分析

Level of Serum Homocysteine and High-sensitivity C-reactive Protein in Male Obese Patients with Masked Hypertension
下载PDF
导出
摘要 目的探讨肥胖伴隐性高血压(MH)患者血清同型半胱氨酸(Hcy)及高敏C反应蛋白(hs-CRP)水平的变化及临床意义。方法选取诊所血压(CBP)正常的肥胖患者78例,均行24h动态血压(ABP)检查,按日间血压检测结果,将肥胖患者分为单纯肥胖组(肥胖组)43例和肥胖伴MH组(MH组)35例;同时选取30例体重正常的健康体检者作为对照。对比分析3组血清Hcy、hs-CRP水平。结果肥胖组MH发病率44.87%(35/78),显著高于对照组的11.43%(P<0.01);肥胖伴MH组的24h平均收缩压、舒张压(24hSB、24hDBP),日、夜平均收缩压(dSBP、dDBP)均明显高于单纯肥胖组和对照组,其血清Hcy、hs-CRP水平也显著高于单纯肥胖组(P<0.05)和对照组(P<0.01);单纯肥胖组血清Hcy、hs-CRP水平与对照组比较无统计学意义。结论肥胖患者MH发病率显著高于对照组,其血清Hcy、hs-CRP水平也明显升高。提示血清Hcy、hs-CRP可能参与了肥胖患者并发高血压的发生、发展过程。 Objective To study the clinical significance of the serum homocysteine(Hcy) and high-sensitivity C-reactive protein(hs-CRP) in obese patients with masked hypertension(MH).Methods Seventy-eight obese patients with normal clinic blood pressure(CBP) were divided into two groups according to the result of daytime blood pressure of ambulatory blood pressure monitoring(ABPM):Obesity with MH(n=35),obesity(n=43).Thirty healthy subjects with normal weight were selected as controls.The Hcy and hs-CRP were measured and assessed in three groups.Results The 24 h SBP,4 h DBP,dSBP,and dDBP in obesity with MH group were significantly higher than that in the other two groups(P0.01).The Hcy and hs-CRP in obesity with MH group were also higher than in obesity group and control group(P0.05 or P0.01).The Hcy and hs-CRP in obesity were higher than that in control group,but there were no significant difference.Conclusion There were high level of the Hcy and hs-CRP in obese patients,especially in obesity with MH.The Hcy and hs-CRP might be involved the occurrence and development process of hypertension in obese patients.
机构地区 海军总医院
出处 《中西医结合心脑血管病杂志》 2012年第12期1423-1425,共3页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 肥胖 隐性高血压 同型半胱氨酸 高敏C反应蛋白 obesity masked hypertension homocysteine high-sensitivity C-reactive protein
  • 相关文献

参考文献12

  • 1Fagard RH,Cornelissen VA. lncidence of cardiovascular events in white- coat,masked and sustained hypertension versus true nor motension:A meta- analysis[J].J Hypertens, 2007,25(11):2193 - 2198.
  • 2Wald DS,Law M,Morris JK,etal. Homocysteine and cardiovascu- lar disease:Evidence on causality from a meta- analysis[J]. BMJ, 2002,325(7374) :1202 - 1206.
  • 3Anuurad E,Shiwaku K,Nogi A,et al. The new BMI criteria for A sians hy the regional o{fice for the Western Pacific Region of WHO are suitable {or screening overweight to prevent metabolic syn drome in elder Japanese workers[J]. J Occup Health,g003,45(6) : 335 - 343.
  • 4刘丽芳,谢晋湘,晋库根,王晋祥,牛爱萍,张培湘,杜志凌,刘力生.隐性高血压病人中心动脉压及增强指数[J].高血压杂志,2005,13(12):771-775. 被引量:29
  • 5Bobrie G,Clerson P,Menard J,et al. Masked hypertension:A sys tematic review[J]. J Hypertens,2008,26(9) : 1715 - 1725.
  • 6Dayal S, Arning E, Bottiglieri T,et al. Cerebral vascular dysfunc tion mediated by superoxide in hyperhomocysteinemic mice[J]. Stroke,2004,35(8) :19,57 - 1962.
  • 7Sen U, Moshal KS, Tyagi N, et al. Homocysteine - induced rayofi broblast differentiation in mouse aortic endothelial cells[J]. J (.;ell Physiol,2006,209(3) :767 - 774.
  • 8Asferg C, J ensen JS, Marott JL, et al. Markers of inflammation and hemodynamic measurements in obesity: Copenhagen City Heart Study[J]. Am J Hypertens,2009,22(4):451 -456.
  • 9Madsen EL,Rissanen A,Bruun JM,et al. Weight loss larger than 10 is needed for general improvement of levels of circulating adi- ponectin and markers of inflammation in obese subiects:A 3 -year weight loss study[J]. Eur J Endocrinol,2008,158(2) .- 179 - 187.
  • 10Bautista LE, Lopez- Jarami[lo P, Vera LM, et al. Is C- reactive protein an independent risk factor for essential hypertension[J]. J Hypertens,2001,19(5) :857 - 861.

二级参考文献26

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2D.AGOSTINOR B,GRUNDY S,SULIVAN L M,et al.Validation of the Framingham coronary heart disease prediction scores:results of multiple ethnic groups investigation[J] JAMA,2001,286:180-187.
  • 3NHLBI JNC.On prevention.Detection,evaluation and treatment of high blood pressure.Education.program[J].JAMA,2003,289:2560-2572.
  • 4CIFKOVA R,ERDINE S,FAGARD R,et.al.practice guidelines for primary care physicians.2003.ESH/ESC hypertention guildlines[J].Hypertention,2003,21:1779-1786.
  • 5MAXALI M,HUGHES J,KIM Y G,et al.Elevated uric aid increases blood pressure in the rat by a novel crystal-indeoendent mechanism[J].Hypertension,2001,38:1101-1106.
  • 6MAXALI M,HUGHES J, KIM Y G, et al. Elevateduric aid increases blood pressure in the rat by a novel crystal-indeoendent mechanism[J].Hypertension,2001,38:1101-1106.
  • 7KANELLIS J,KANG D H.Uric acid as a mediator of endot belialdysfunction,inflammation and vascular disease[J].Semin Nephrol,2005,25:39-42.
  • 8VENUGOPAL S K,DEVARAJ S,YUHANNAN I,et al.Demonstration that C-reactive protein decreases eNOs expression and bioactivity in human aortic endothelial cells[J].Circulation,2002,106:1439-1441.
  • 9HAYAISHI-OKANO R,YAMASAKI Y,KATAKAMI N,et al.Elevated creactive protein associates with early stage carotid atherosclerosis in young subjects with type 1 diabetes[J].Diabetes Care,2002,25:1432-1438.
  • 10Devereux RB,Pickering TG.Ambulatory blood pressure in assessing the cardiac impact and prognosis of hypertension.In:O'Brien E,O' Malley K,eds.Blood pressure Measurement.Handbook of Hypertension[M]//V 14.Amsterdam:Elsevier.1991:261-285.

共引文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部